Frederick Locke, MD
Moffitt Cancer Center, Blood and Marrow Transplant and Cellular Immunotherapy
Dr. Fred Locke is a prominent medical oncologist and translational researcher specializing in cellular immunotherapy. He leads the Immune Cell Therapy (ICE-T) initiative at Moffitt Cancer Center, where he serves in the Department of Blood and Marrow Transplant and Cellular Immunotherapy.
Dr. Locke is a clinical research leader in chimeric antigen receptor (CAR) T-cell therapy, acting as a national principal investigator for several pivotal trials of anti-CD19 CARs for lymphoma. His work bridges laboratory discoveries with clinical applications, translating findings into new cellular immunotherapies such as a whole protein surviving tumor vaccine for multiple myeloma.
After earning his M.D. from Wayne State University, Dr. Locke completed his residency there and received further training in medical oncology, clinical research, and laboratory research at the University of Chicago.
At Moffitt, Dr. Locke provides care for patients with multiple myeloma, lymphoma, and leukemia. He oversees both autologous and allogeneic hematopoietic stem cell transplants, as well as cellular immunotherapy treatments like CAR T-cell therapy.
Dr. Locke’s research focuses on developing and optimizing cell therapies for various hematological malignancies. He is involved in numerous clinical trials, including studies on CAR T-cell therapies for large B-cell lymphoma and multiple myeloma.
His expertise in cellular immunotherapy has contributed significantly to the field, particularly in advancing CAR T-cell treatments and understanding their safety and efficacy profiles in real-world settings.